Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014.

This Pulmonary Perspective summarizes the content and main conclusions of an international workshop on personalized respiratory medicine coorganized by the Barcelona Respiratory Network ( www.brn.cat ) and the AJRCCM in June 2014. It discusses (1) its definition and historical, social, legal, and ethical aspects; (2) the view from different disciplines, including basic science, epidemiology, bioinformatics, and network/systems medicine; (3) the bottlenecks and opportunities identified by some currently ongoing projects; and (4) the implications for the individual, the healthcare system and the pharmaceutical industry. The authors hope that, although it is not a systematic review on the subject, this document can be a useful reference for researchers, clinicians, healthcare managers, policy-makers, and industry parties interested in personalized respiratory medicine.

[1]  P. Poole,et al.  Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. , 2017, The Cochrane database of systematic reviews.

[2]  Craig E Wheelock,et al.  Network analysis in the investigation of chronic respiratory diseases. From basics to application. , 2014, American journal of respiratory and critical care medicine.

[3]  Avrum Spira,et al.  Relationship of DNA methylation and gene expression in idiopathic pulmonary fibrosis. , 2014, American journal of respiratory and critical care medicine.

[4]  Pablo Villoslada,et al.  Modules, networks and systems medicine for understanding disease and aiding diagnosis , 2014, Genome Medicine.

[5]  Colm E. Nestor,et al.  Targeted omics and systems medicine: personalising care. , 2014, The Lancet. Respiratory medicine.

[6]  J. Roca,et al.  Network medicine analysis of COPD multimorbidities , 2014, Respiratory Research.

[7]  A. Agustí,et al.  Network medicine, multimorbidity and the lung in the elderly , 2014, European Respiratory Journal.

[8]  N. McElvaney,et al.  Ivacaftor: from bench to bedside... and back again. , 2014, American journal of respiratory and critical care medicine.

[9]  Russell Bowler,et al.  Analyzing networks of phenotypes in complex diseases: methodology and applications in COPD , 2014, BMC Systems Biology.

[10]  S. Schneeweiss.  Learning from big health care data. , 2014, The New England journal of medicine.

[11]  W. Busse,et al.  Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. , 2014, The Journal of allergy and clinical immunology.

[12]  Gary D Bader,et al.  A draft map of the human proteome , 2014, Nature.

[13]  V. Roger,et al.  From 'solution shop' model to 'focused factory' in hospital surgery: increasing care value and predictability. , 2014, Health affairs.

[14]  Christina Kiel,et al.  Structure‐energy‐based predictions and network modelling of RASopathy and cancer missense mutations , 2014, Molecular systems biology.

[15]  A. Agustí.  The path to personalised medicine in COPD , 2014, Thorax.

[16]  Christoph Lange,et al.  Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis. , 2014, The Lancet. Respiratory medicine.

[17]  Stephanie A. Santorico,et al.  Cluster analysis in the COPDGene study identifies subtypes of smokers with distinct patterns of airway disease and emphysema , 2014, Thorax.

[18]  D. Postma,et al.  Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. , 2014, The Lancet. Respiratory medicine.

[19]  Stephen Fairclough,et al.  Physiological data must remain confidential , 2014, Nature.

[20]  J. Sznajder,et al.  Malfolded protein structure and proteostasis in lung diseases. , 2013, American journal of respiratory and critical care medicine.

[21]  G. Annas,et al.  23andMe and the FDA. , 2014, New England Journal of Medicine.

[22]  Alex Gray,et al.  The bottom–up approach to defining life: deciphering the functional organization of biological cells via multi-objective representation of biological complexity from molecules to cells , 2013, Front. Physiol..

[23]  R. Varadhan,et al.  Benefits and harms of roflumilast in moderate to severe COPD , 2013, Thorax.

[24]  Jill P. Mesirov,et al.  Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.

[25]  Jill P Mesirov,et al.  Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration , 2013, BMC Medicine.

[26]  F. Sanz,et al.  Improving data and knowledge management to better integrate health care and research , 2013, Journal of internal medicine.

[27]  T. Maher.  Beyond the diagnosis of idiopathic pulmonary fibrosis; the growing role of systems biology and stratified medicine , 2013, Current opinion in pulmonary medicine.

[28]  D. Belsky,et al.  Polygenic risk and the development and course of asthma: an analysis of data from a four-decade longitudinal study. , 2013, The Lancet. Respiratory medicine.

[29]  J. Gray,et al.  The shift to personalised and population medicine , 2013, The Lancet.

[30]  Chris Henshall,et al.  HEALTH TECHNOLOGY ASSESSMENT, VALUE-BASED DECISION MAKING, AND INNOVATION , 2013, International Journal of Technology Assessment in Health Care.

[31]  I. Pavord,et al.  Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms? , 2013, Thorax.

[32]  B. Nordestgaard,et al.  Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. , 2013, JAMA.

[33]  T. Beaty,et al.  Gene expression analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells. , 2013, Genomics.

[34]  T. Murdoch,et al.  The inevitable application of big data to health care. , 2013, JAMA.

[35]  M. Porter,et al.  Redesigning primary care: a strategic vision to improve value by organizing around patients' needs. , 2013, Health affairs.

[36]  I. Hall,et al.  Stratified medicine: drugs meet genetics , 2013, European Respiratory Review.

[37]  Charles Auffray,et al.  Application of ’omics technologies to biomarker discovery in inflammatory lung diseases , 2013, European Respiratory Journal.

[38]  E. Silverman,et al.  Developing New Drug Treatments in the Era of Network Medicine , 2013, Clinical pharmacology and therapeutics.

[39]  M. Khoury,et al.  A Population Perspective on How Personalized Medicine Can Improve Health , 2013 .

[40]  F. García Lizana.  [European Innovation Partnership on active and healthy ageing]. , 2013, Medicina clinica.

[41]  S. Lewitzky,et al.  A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients , 2011, The Pharmacogenomics Journal.

[42]  R. Varadhan,et al.  A framework for organizing and selecting quantitative approaches for benefit-harm assessment , 2012, BMC Medical Research Methodology.

[43]  A. Ciechanover,et al.  Personalized medicine: the road ahead. , 2012, American journal of respiratory and critical care medicine.

[44]  Alvar Agusti,et al.  The COPD control panel: towards personalised medicine in COPD , 2012, Thorax.

[45]  D. Geman,et al.  Computational Medicine: Translating Models to Clinical Care , 2012 .

[46]  K. Rabe,et al.  Uncovering and tackling Europe's hidden respiratory illness , 2012, The Lancet.

[47]  Edwin K Silverman,et al.  Network medicine approaches to the genetics of complex diseases. , 2012, Discovery medicine.

[48]  L. Smarr.  Quantifying your body: a how-to guide from a systems biology perspective. , 2012, Biotechnology journal.

[49]  Charles Auffray,et al.  Editorial: Systems biology and personalized medicine – the future is now , 2012, Biotechnology journal.

[50]  S. Wyke,et al.  Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study , 2012, The Lancet.

[51]  Muin J Khoury,et al.  A population approach to precision medicine. , 2012, American journal of preventive medicine.

[52]  Courtney Crim,et al.  Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype , 2012, PloS one.

[53]  P. Sorger,et al.  Sequential Application of Anticancer Drugs Enhances Cell Death by Rewiring Apoptotic Signaling Networks , 2012, Cell.

[54]  D. Postma,et al.  Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) seminar. , 2012, The Journal of allergy and clinical immunology.

[55]  Hugo Y. K. Lam,et al.  Personal Omics Profiling Reveals Dynamic Molecular and Medical Phenotypes , 2012, Cell.

[56]  Ara Darzi,et al.  Preparing for precision medicine. , 2012, The New England journal of medicine.

[57]  Ben Lehner,et al.  Fitness Trade-Offs and Environmentally Induced Mutation Buffering in Isogenic C. elegans , 2012, Science.

[58]  J. Schwartz,et al.  Expanding the scope of environmental risk assessment to better include differential vulnerability and susceptibility. , 2011, American journal of public health.

[59]  Thomas Beyer,et al.  Medical imaging in personalised medicine: a white paper of the research committee of the European Society of Radiology (ESR) , 2011, Insights into imaging.

[60]  Josep Roca,et al.  A Systems Biology Approach Identifies Molecular Networks Defining Skeletal Muscle Abnormalities in Chronic Obstructive Pulmonary Disease , 2011, PLoS Comput. Biol..

[61]  L. Hood,et al.  Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.

[62]  A. Bauer-Mehren,et al.  Gene-Disease Network Analysis Reveals Functional Modules in Mendelian, Complex and Environmental Diseases , 2011, PloS one.

[63]  F Kauffmann,et al.  MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine , 2011, Allergy.

[64]  Adnan Custovic,et al.  Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. , 2011, The Journal of allergy and clinical immunology.

[65]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[66]  Laura Inés Furlong,et al.  DisGeNET: a Cytoscape plugin to visualize, integrate, search and analyze gene-disease networks , 2010, Bioinform..

[67]  R. Epstein,et al.  Comparative effectiveness and personalized medicine: evolving together or apart? , 2010, Health affairs.

[68]  K. Gibert,et al.  Integrating clinicians, knowledge and data: expert-based cooperative analysis in healthcare decision support , 2010, Health research policy and systems.

[69]  E. Perakslis,et al.  Effective knowledge management in translational medicine , 2010, Journal of Translational Medicine.

[70]  Teri A Manolio,et al.  Genomewide association studies and assessment of the risk of disease. , 2010, The New England journal of medicine.

[71]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[72]  Brian Godman,et al.  Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers , 2010, BMC health services research.

[73]  Charles Auffray,et al.  An integrative systems biology approach to understanding pulmonary diseases. , 2010, Chest.

[74]  J. Kere,et al.  ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[75]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .

[76]  M. Porter.  A strategy for health care reform--toward a value-based system. , 2009, The New England journal of medicine.

[77]  S. Tunis,et al.  Does comparative-effectiveness research threaten personalized medicine? , 2009, The New England journal of medicine.

[78]  M. Vidal,et al.  Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.

[79]  C. Fu,et al.  Study on Mass Customization for Knowledge Production and its Operation Mode , 2009 .

[80]  Ulrike Held,et al.  Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index , 2009, The Lancet.

[81]  Christina Kiel,et al.  Cell Type–Specific Importance of Ras–c-Raf Complex Association Rate Constants for MAPK Signaling , 2009, Science Signaling.

[82]  David J. Galas,et al.  Systems Biology and Emerging Technologies Will Catalyze the Transition from Reactive Medicine to Predictive, Personalized, Preventive and Participatory (P4) Medicine , 2009 .

[83]  K. Shianna,et al.  A Genome-Wide Association Study in Chronic Obstructive Pulmonary Disease (COPD): Identification of Two Major Susceptibility Loci , 2009, PLoS genetics.

[84]  J. Ioannidis.  Personalized Genetic Prediction: Too Limited, Too Expensive, or Too Soon? , 2009, Annals of Internal Medicine.

[85]  L. Hood,et al.  Systems medicine: the future of medical genomics and healthcare , 2009, Genome Medicine.

[86]  A. Barabasi,et al.  Network medicine--from obesity to the "diseasome". , 2007, The New England journal of medicine.

[87]  A. Barabasi,et al.  Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.

[88]  P. Lansdorp,et al.  Telomerase mutations in families with idiopathic pulmonary fibrosis. , 2007, The New England journal of medicine.

[89]  Jeremy J. W. Chen,et al.  A five-gene signature and clinical outcome in non-small-cell lung cancer. , 2007, The New England journal of medicine.

[90]  Barbara Di Ventura,et al.  From in vivo to in silico biology and back , 2006, Nature.

[91]  Eric J Kunkel,et al.  Systems biology in drug discovery. , 2006, Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual Conference.

[92]  F. Kauffmann,et al.  Post-genome respiratory epidemiology: a multidisciplinary challenge , 2004, European Respiratory Journal.

[93]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[94]  Ciro Casanova,et al.  The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. , 2004, The New England journal of medicine.

[95]  Allen W Cowley.  The elusive field of systems biology. , 2004, Physiological genomics.

[96]  M H Gail,et al.  Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. , 1999, Journal of the National Cancer Institute.

[97]  A. Detsky,et al.  Evidence-based medicine. A new approach to teaching the practice of medicine. , 1992, JAMA.

[98]  D. Mccormick.  Sequence the Human Genome , 1986, Bio/Technology.

[99]  A. Gittelsohn,et al.  Small Area Variations in Health Care Delivery , 1973, Science.

[100]  S. Doll.  Smoking and Lung Cancer , 1957, Nature.